中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
8期
513-517
,共5页
卵巢肿瘤%肿瘤标记%生物学%CA-125抗原%危险性评估%预测%人附睾蛋白4
卵巢腫瘤%腫瘤標記%生物學%CA-125抗原%危險性評估%預測%人附睪蛋白4
란소종류%종류표기%생물학%CA-125항원%위험성평고%예측%인부고단백4
ovarian neoplasms%tumor markers%biological%CA-125 antigen%risk assessment%forecasting%human epididymis pro-tein 4
目的：探讨血清人附睾蛋白4（Human epididymis protein 4 HE4）和癌抗原125（CA125）联合检测（卵巢恶性风险计算法ROMA）预测盆腔包块患者上皮性卵巢癌（EOC）风险。方法：采用电化学发光法检测因盆腔包块或卵巢囊肿住院拟行手术的患者血清HE4和CA125水平，根据是否绝经，采用ROMA方法计算卵巢癌预测概率（PP），绘制受试者工作曲线（ROC），分别确定绝经前后临界值，并将患者划分至高危组和低危组，评估预测模型的应用价值。结果：评估了1683例患者，其中1448例盆腔良性疾病，235例盆腔恶性肿瘤，包括106例EOC。在经病理确诊为良性盆腔包块患者中有1356例被划分至低危组，特异性93.6%；盆腔恶性肿瘤中121例划分至高危组，敏感度80.7%；卵巢交界性上皮瘤20例划分至高危组，敏感度28.2%；EOC中93例划分至高危组，敏感度87.7%，未划分至高危组包括黏液性腺癌2例，透明细胞癌11例。卵巢非上皮性恶性肿瘤患者中5例划分至高危组，敏感度38.5%；非卵巢恶性肿瘤患者中35例划分至高危组，敏感度85.3%；转移性卵巢癌患者中1例划分至高危组，敏感度25.0%。结论：ROMA较成功地将盆腔恶性肿瘤患者划分至高危组，其中EOC患者大部分被正确地划分至高危组，ROMA在诊断恶性肿瘤尤其是EOC方面具有较高的应用价值。
目的：探討血清人附睪蛋白4（Human epididymis protein 4 HE4）和癌抗原125（CA125）聯閤檢測（卵巢噁性風險計算法ROMA）預測盆腔包塊患者上皮性卵巢癌（EOC）風險。方法：採用電化學髮光法檢測因盆腔包塊或卵巢囊腫住院擬行手術的患者血清HE4和CA125水平，根據是否絕經，採用ROMA方法計算卵巢癌預測概率（PP），繪製受試者工作麯線（ROC），分彆確定絕經前後臨界值，併將患者劃分至高危組和低危組，評估預測模型的應用價值。結果：評估瞭1683例患者，其中1448例盆腔良性疾病，235例盆腔噁性腫瘤，包括106例EOC。在經病理確診為良性盆腔包塊患者中有1356例被劃分至低危組，特異性93.6%；盆腔噁性腫瘤中121例劃分至高危組，敏感度80.7%；卵巢交界性上皮瘤20例劃分至高危組，敏感度28.2%；EOC中93例劃分至高危組，敏感度87.7%，未劃分至高危組包括黏液性腺癌2例，透明細胞癌11例。卵巢非上皮性噁性腫瘤患者中5例劃分至高危組，敏感度38.5%；非卵巢噁性腫瘤患者中35例劃分至高危組，敏感度85.3%；轉移性卵巢癌患者中1例劃分至高危組，敏感度25.0%。結論：ROMA較成功地將盆腔噁性腫瘤患者劃分至高危組，其中EOC患者大部分被正確地劃分至高危組，ROMA在診斷噁性腫瘤尤其是EOC方麵具有較高的應用價值。
목적：탐토혈청인부고단백4（Human epididymis protein 4 HE4）화암항원125（CA125）연합검측（란소악성풍험계산법ROMA）예측분강포괴환자상피성란소암（EOC）풍험。방법：채용전화학발광법검측인분강포괴혹란소낭종주원의행수술적환자혈청HE4화CA125수평，근거시부절경，채용ROMA방법계산란소암예측개솔（PP），회제수시자공작곡선（ROC），분별학정절경전후림계치，병장환자화분지고위조화저위조，평고예측모형적응용개치。결과：평고료1683례환자，기중1448례분강량성질병，235례분강악성종류，포괄106례EOC。재경병리학진위량성분강포괴환자중유1356례피화분지저위조，특이성93.6%；분강악성종류중121례화분지고위조，민감도80.7%；란소교계성상피류20례화분지고위조，민감도28.2%；EOC중93례화분지고위조，민감도87.7%，미화분지고위조포괄점액성선암2례，투명세포암11례。란소비상피성악성종류환자중5례화분지고위조，민감도38.5%；비란소악성종류환자중35례화분지고위조，민감도85.3%；전이성란소암환자중1례화분지고위조，민감도25.0%。결론：ROMA교성공지장분강악성종류환자화분지고위조，기중EOC환자대부분피정학지화분지고위조，ROMA재진단악성종류우기시EOC방면구유교고적응용개치。
Objective:This study aims to evaluate the performance of the predictive model risk of ovarian malignancy algorithm (ROMA) using serum human epididymis protein 4 (HE4) and CA125 for discriminating benign from malignant pelvic masses. Meth-ods:The electrochemical luminescence method was carried out before and after the menopause prediction model (ROMA) to detect se-rum HE4 and CA125 levels of patients admitted in hospital for surgery of pelvic masses or ovarian cyst. Patients were classified into high-and low-risk groups to evaluate the value of the applied prediction model. Results:Of the 1683 patients evaluated, 1448 had pel-vic benign disease and 235 had pelvic malignancy, including 106 EOC. In the pathological diagnosis of patients with benign pelvic masses, 1356 cases were classified into the low-risk group with a specificity of 93.6%. A total of 121 cases of pelvic malignant tumors with sensitivity of 80.7%and 20 cases of border ovarian epithelial tumor with sensitivity of 28.2%were categorized in the high-risk group. EOC cases (93) were also classified in the high-risk group, with sensitivity of 87.7%. The cases that were not classified in the high-risk group included 2 of mucous adenocarcinoma and 11 of clear cell carcinoma. Five cases of non-epithelial ovarian malignant tu-mor patients were classified into the high-risk group with a sensitivity of 38.5%. Thirty-five cases of ovarian malignant tumor patients with a sensitivity of 85.3% and one case of metastatic ovarian cancer patient with a sensitivity of 25.0% were categorized in the high-risk group. Conclusions: ROMA can be successfully applied in pelvic malignant tumor patients to classify them into high-risk group. Most EOC patients belong to the high-risk group. ROMA can be used in patients with malignant EOC, especially during prelimi-nary screening.
